Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
TBPH 
Theravance Biopharma Inc (TBPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: TBPH (3-star) is a STRONG-BUY. BUY since 134 days. Simulated Profits (58.99%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26.71
1 Year Target Price $26.71
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 13.41% | Avg. Invested days 46 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 895.89M USD | Price to earnings Ratio 31.02 | 1Y Target Price 26.71 |
Price to earnings Ratio 31.02 | 1Y Target Price 26.71 | ||
Volume (30-day avg) 4 | Beta 0.14 | 52 Weeks Range 7.90 - 20.33 | Updated Date 12/12/2025 |
52 Weeks Range 7.90 - 20.33 | Updated Date 12/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 36.53% | Operating Margin (TTM) -32.29% |
Management Effectiveness
Return on Assets (TTM) -5.32% | Return on Equity (TTM) 14.03% |
Valuation
Trailing PE 31.02 | Forward PE 14.37 | Enterprise Value 607256509 | Price to Sales(TTM) 11.15 |
Enterprise Value 607256509 | Price to Sales(TTM) 11.15 | ||
Enterprise Value to Revenue 7.56 | Enterprise Value to EBITDA 11.44 | Shares Outstanding 50672431 | Shares Floating 22394174 |
Shares Outstanding 50672431 | Shares Floating 22394174 | ||
Percent Insiders 4.06 | Percent Institutions 97.17 |
Upturn AI SWOT
Theravance Biopharma Inc
Company Overview
History and Background
Theravance Biopharma, Inc. was founded in 2013 as a spin-off from Theravance, Inc. The company focuses on the discovery, development, and commercialization of novel medicines. It operates with a lean model, leveraging strategic partnerships to advance its pipeline.
Core Business Areas
- Therapeutic Areas: Theravance Biopharma's core business is focused on developing therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). They also explore other unmet medical needs.
Leadership and Structure
Theravance Biopharma operates with a management team and a board of directors overseeing its strategic direction and operations. The company's structure is designed for efficient drug development and partnership management.
Top Products and Market Share
Key Offerings
- Competitors: Gilead Sciences (Stiolto Respimat, Tudorza),Boehringer Ingelheim (Spiriva),GlaxoSmithKline (Anoro Ellipta, Trelegy Ellipta),AstraZeneca (Symbicort, Daliresp)
- Description: YUPELRI is a long-acting muscarinic antagonist (LAMA) for the once-daily treatment of symptomatic chronic obstructive pulmonary disease (COPD) in patients in the United States. It is marketed by Theravance Biopharma's partner, Covis Pharma.
- Market Share: As of recent reports, specific market share data for YUPELRI within the broader COPD market is not publicly disclosed with granular detail. The COPD market is highly competitive.
- Product Name: YUPELRI (revefenacin) extended-release capsules
Market Dynamics
Industry Overview
The respiratory disease market, particularly for COPD, is a significant and growing sector driven by aging populations, environmental factors, and smoking rates. The market is characterized by a need for improved treatment options that offer better efficacy, convenience, and safety profiles.
Positioning
Theravance Biopharma positions itself as a company focused on developing innovative therapies for underserved respiratory conditions. Its strategy often involves developing novel mechanisms of action and leveraging partnerships for commercialization.
Total Addressable Market (TAM)
The global COPD market is substantial, with projections indicating significant growth. Estimates vary, but the market is valued in the tens of billions of dollars annually and is expected to continue expanding. Theravance Biopharma, through its lead product YUPELRI and pipeline, aims to capture a share of this significant market.
Upturn SWOT Analysis
Strengths
- Focus on a specific therapeutic area (respiratory diseases) with a clear unmet need.
- Partnership model can reduce development costs and accelerate market access.
- Experienced management team with a track record in drug development.
Weaknesses
- Reliance on partners for commercialization, which can impact revenue recognition and control.
- Relatively small pipeline compared to larger pharmaceutical companies.
- Limited financial resources as a smaller biopharma company.
Opportunities
- Increasing global prevalence of respiratory diseases.
- Potential for further pipeline development and expansion into related therapeutic areas.
- Strategic collaborations to access new markets or technologies.
Threats
- Intense competition from established pharmaceutical giants.
- Regulatory hurdles and the high cost of drug development and approval.
- Patent expirations and the emergence of generic alternatives.
- Changes in healthcare policy and reimbursement.
Competitors and Market Share
Key Competitors
- Gilead Sciences (GILD)
- Boehringer Ingelheim (Private)
- GlaxoSmithKline (GSK)
- AstraZeneca (AZN)
Competitive Landscape
Theravance Biopharma operates in a highly competitive landscape dominated by large pharmaceutical companies with extensive resources and established market presence. Its competitive advantages lie in its specialized focus, potential for innovative therapies, and agile operating model, but it faces significant challenges in competing on scale and market penetration against larger players.
Growth Trajectory and Initiatives
Historical Growth: Theravance Biopharma's growth trajectory has been shaped by its strategic focus on developing and partnering its pipeline. Growth is often measured by advancements in clinical trials, successful regulatory approvals, and the revenue generated from its partnered products.
Future Projections: Future growth projections are typically based on the progression of its pipeline candidates through clinical development, potential new partnerships, and the performance of its marketed products (through partners). Analyst estimates should be consulted for forward-looking guidance.
Recent Initiatives: Recent initiatives likely involve advancing its existing pipeline candidates, exploring new therapeutic targets, and potentially seeking new strategic collaborations to enhance its development and commercialization capabilities.
Summary
Theravance Biopharma Inc. is a biopharmaceutical company focused on respiratory diseases, with YUPELRI as its key marketed product, partnered with Covis Pharma. The company's strengths lie in its specialized focus and partnership model. However, it faces significant challenges from larger competitors and relies heavily on its partners for commercial success. Future growth hinges on pipeline advancements and the performance of its partnered assets.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Investor Relations Websites
- SEC Filings (10-K, 10-Q)
- Industry Market Research Reports
- Financial News Outlets
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Data accuracy and completeness are not guaranteed. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is estimated and may not be precisely reflective of current market conditions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theravance Biopharma Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2014-05-16 | CEO & Director Mr. Rick E. Winningham M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 97 | Website https://www.theravance.com |
Full time employees 97 | Website https://www.theravance.com | ||
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.